RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States.
The drug was recently approved by the Food and Drug Administration to treat bronchospasm associated with chronic obstructive pulmonary disease — including chronic bronchitis and emphysema — and to reduce exacerbations in COPD patients, the company stated. The company's Spiriva Handihaler (tiotropium bromide inhalation powder) will still be available for patients.
“For 10 years, Spiriva HandiHaler has been a trusted maintenance therapy for patients with COPD, and Boehringer Ingelheim is proud to now offer another inhaler choice, Spiriva Respimat,” said Danny McBryan, MD, VP, clinical development and medical affairs, respiratory, Boehringer Ingelheim Pharmaceuticals. “Spiriva Respimat represents Boehringer Ingelheim’s continuing commitment to the COPD community to provide new treatment options.”
Boehringer Ingelheim is offering a savings care allowing eligible patients to receive Spiriva Respimat for as low as $10, depending on their insurance coverage. The card is available at Spiriva.com and can be activated at most pharmacies, the company said.